BROWNSTEIN HYATT FARBER SCHRECK, LLP

Lobbying for ABBVIE · Biopharmaceutical company

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · District of Columbia · House · Senate · $90,000.00 income · posted Apr 15, 2026

Lobbying activity 2

Health Issues

Issues related to patient access, pharmaceutical manufacturing, Patent reform, and drug pricing both domestic and international Issues realted to medicare drug pricing and reimbursement DTC Advertising

Consumer Issues/Safety/Products

Issues related to potential privacy legislation

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.